

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

TOUMAI[®] LAPAROSCOPIC SURGICAL ROBOT COMPLETED THE FIRST 5G REMOTE SURGERY

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that by using 5G connection between the People’s Hospital of Jiangsu Province and the People’s Hospital of Kizilsu Kirghiz Prefecture in Xinjiang, the Group’s self-developed Toumai[®] Laparoscopic Surgical Robot (“**Toumai**”) has successfully completed the longest-distance 5G ultra-remote robotic surgery in the world to date.

ABOUT TOUMAI

Toumai is a domestic laparoscopic surgical robot independently developed by the Group and has been approved for marketing by the National Medical Products Administration in January 2022. It is the first and only Chinese-developed four-arm laparoscopic surgical robot approved for marketing as of the date of this announcement. Toumai’s clinical advantages include realistic three-dimensional surgical field vision and high-dexterity robot arm surgical instrument, and Toumai has fully demonstrated its efficacy and safety in clinical trials. With 5G remote technology, Toumai can minimize the latency of imaging and manipulation by taking advantage of three-dimensional imagery synchronous transmission and reproduction technology, it also allows real-time network communication quality monitoring and the issuing of early warnings, in order to ensure a safe and smooth surgery.

IMPACT ON THE COMPANY

In recent years, remote surgery has been the key focus in the medical fields. The use of 5G transmission technology may further solve technical bottlenecks for performing surgeries at hospitals in remote and underdeveloped areas, and make it more feasible to carry out surgeries of high complexity and difficulty. At the same time, remote surgery can save the need for patients to travel long distances to receive surgical treatment, instead they can receive the same treatment from top industry experts whilst staying in their local area.

As the four-arm laparoscopic surgical robot that uses 5G technology to complete the farthest distance remote surgery in the world to date, Toumai fully demonstrates the technical strength and advantages in the research and development of Chinese developed surgical robots. Furthermore, it lays the foundation for “Intelligent Manufacturing in China”. In the future, the Group will focus on the application of 5G technology in more surgeries assisted by Toumai, with aims to provide more solutions in trickling down high-quality medical resources, narrowing the differences between the different classes of diagnosis and treatment, and reducing the financial burden on patients. The Group will continue to adhere to our belief to “make surgery easier, safer, and less invasive”.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 12 June 2022

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Ms. Lee Kit Ying, Dr. Li Minghua and Mr. Yao Haisong.